#40 – Hantaan Virus: From the Korean War to the Rats in Your City
Recorded in Seoul, this episode is about Hantaan virus, the prototype hantavirus that gave the whole group its name. Florian Krammer explains how the disease first appeared during the Korean War in more than 3,000 soldiers, how virologist Ho-Wang Lee traced it to the striped field mouse in 1976 and isolated the virus two years later, and why the Hantan River is spelled with one A while the virus has two. The illness is known as Korean hemorrhagic fever with renal syndrome: after an incubation period of usually twelve to sixteen days come flu-like symptoms, a hypotensive phase, and a renal phase that often requires dialysis. The case fatality rate is around six percent today, with China reporting 9,000 to 12,000 cases a year and South Korea 400 to 600. The episode also covers Seoul virus, discovered by the same researcher in 1980: carried by Norway rats, it has spread worldwide with them and was found in about ten percent of rats sampled in New York City. Pet rats deserve particular attention after an outbreak across the US and Canada in 2016 and 2017. Overview of hemorrhagic fever with renal syndrome in Asia: https://pmc.ncbi.nlm.nih.gov/articles/PMC9966805/ Review about Seoulvirus in rats: https://pmc.ncbi.nlm.nih.gov/articles/PMC6669632/ Report about 2017 Seoulvirus outbreak in the US: https://pmc.ncbi.nlm.nih.gov/articles/PMC5794350/ +++++ You can support the podcast via our German Steady page: https://steady.page/virologisch/ Questions, feedback or topic suggestions? Feel free to contact us at: virological@podcastwerkstatt.com +++++ Krammer laboratory information Krammer Laboratory at the Icahn School of Medicine at Mount Sinai https://labs.icahn.mssm.edu/krammerlab/ Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness https://soap.lbg.ac.at/ Ignaz Semmelweis Institute https://semmelweisinstitute.ac.at/ +++++ Conflict of interest statement The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company. I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico). My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines. My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense. My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
- Transcript